MHRA says quality system deficiencies are most common issue from inspections

By Zachary Brennan

- Last updated on GMT

MHRA says quality system deficiencies are most common issue

Related tags Quality management system

Deficiencies related to manufacturers’ quality systems are by far the most prevalent issue cited from inspections by the UK’s MHRA (Medicines and Healthcare Products Regulatory Agency), the agency said in a report on 2013 inspections.

The agency broke down its inspection work over the last five years and found that the ratio of major deficiencies raised per inspection has remained relatively constant, and even decreased since 2009. But the ratio of critical deficiencies remained constant until 2013, when the agency reported “a cluster of data integrity issues with potential impact to public health.​”

Data integrity issues -- both as a result of bad practice and to “a significantly lesser extent intentional fraud​” -- have been observed by the agency across all locations and sectors of the industry. “There will therefore be a focus on this area during inspections in the near future​,” the agency says.  

The MHRA also observed that the relative number of critical deficiencies raised per inspection in a given continent is higher in Asia than the other continents.

In addition, the most frequently encountered defect categories raised over the previous five years have remained relatively consistent, though there has been a significant increase in physical or chemical contaminations.

There has been a general trend towards higher potency active substances, therefore increasing the potential for a contamination event to have a greater impact​,” the MHRA says.

The analysis observed 630 GMP inspections in 2013, 216 of which resulted in major or critical deficiencies and 174 of those were in the UK while 42 were overseas.

Quality Systems

In offering examples of quality system deficiencies, the MHRA cited the following:

  • No self-inspections carried out in the previous year, nor was there a programme established for the current year;
  • Quality system was not being maintained in that Product Quality Reviews had not been completed during the required period and a significant number of SOPs were past their review date, among other things; and
  • The laboratory pharmaceutical quality system was silent with respect to stability sample management.

Related news

Show more

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...

Follow us


View more